Scope Fluidics – a biotechnological company listed on NewConnect, developer of innovative medical diagnostics projects – has signed a letter of intent to cooperate with German company RKT Rodinger Kunstststoff-Technik GmbH (RKT), which provides professional services related to mass production of cartridges used in medical diagnostic systems. The launch of mass production on a global scale will increase the economic attractiveness of the PCR|ONE system and enable a potential buyer to quickly enter the Point-of-Care diagnostics market.
The aim of cooperation between both companies is to prepare the necessary resources to launch mass production of PCR|ONE cartridges and to optimise manufacturing costs. The contract with an experienced mass producer supports the ongoing process of selling Curiosity Diagnostics to a global distributor of medical diagnostic systems. The mutual intention of the parties to the agreement is to achieve the manufacturing capacity of at least 1 million cartridges annually as soon as possible.
- PCR|ONE offers rapid, comprehensive Point-of-Care genetic diagnostics. The COVID pandemic generates huge demand for fast and reliable detection of SARS-CoV-2 infections. To meet the expectations of our potential buyers, we are preparing the next stage of our product development. We have chosen a business partner with many years of experience in the automated production of modules and disposable polymer devices for pharmacy and medical diagnostics – says Prof. Piotr Garstecki, co-founder, key shareholder and CEO of Scope Fluidics.
The outbreak of the epidemic caused by SARS-Cov-2 has increased the interest of potential buyers in the tests offered by the PCR|ONE technology. The market of Point-of-Care molecular (genetic) diagnostics, which has been developing dynamically for several years, has increased several times during the pandemic. It is expected that the increased demand for genetic Point-of-Care testing will continue for the next few years. Global distributors of diagnostic equipment are looking for technologies that will allow them to enter the market immediately and respond to this demand as quickly as possible.
Scope Fluidics, apart from the planned certification of the PCR|ONE system under the CE-IVD procedure, will carry out up to several thousand tests in Poland and other EU countries. By expanding its activities under the Early Access Programme (making diagnostic systems available to users in the first months after the system certification), the Company will confirm the effectiveness of rapid detection of the SARS-CoV-2 virus in health care centres and other public and private institutions.